Kyorin Pharmaceutical to License Its Overactive Bladder Drug to Korean LG Life Sciences.Tokyo, Japan, Aug 4, 2005 - (JCNN JCNN Japan Corporate News Network ) - Kyorin Pharmaceutical has signed a memorandum of understanding A Memorandum of Understanding (MoU) is a legal document describing a bilateral or multilateral agreement between parties. It expresses a convergence of will between the parties, indicating an intended common line of action and may not imply a legal commitment. with LG Life Sciences (LGLS LGLS Louis Goldberg Library Suppliers (Nazareth, PA) ), a Korean pharmaceutical, concerning licensing KRP-197, Kyorin's proprietary agent used in the treatment of overactive bladder. Under the memorandum, Kyorin will license LGLS to exclusively develop, manufacture, and sell KRP-197 in Korea. Also, for a limited period of time, LGLS will exclusively be able to seek for commercial opportunities in Europe, the US and other countries. Meantime, Kyorin will receive up-front and milestone payments, as well as royalties from LGLS. Details of the agreement will be finalized later on. Currently, Kyorin has applied for approval of KRP-197 under the trade name of Uritos Tablet. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion